We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
What Drives Diffusion of New Cancer Therapies?
- Authors
Schmidt, Charlie
- Abstract
The article discusses a case study on the diffusion of cancer treatment in clinical practice and the approval of the U.S. Food and Drug Administration of the prescription of docetaxel in prostate cancer. Topics include the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute (NCI), the comment of doctor Dawn Hershman on the use of mitoxantrone for prostate cancer treatment, and the statement of doctor Rena Conti on the pattern of docetaxel's trajectory.
- Subjects
DIFFUSION; CANCER treatment; DOCETAXEL; PHYSICIAN practice patterns; UNITED States. Food &; Drug Administration; NATIONAL Cancer Institute (U.S.); HERSMAN, Dawn; CONTI, Rena
- Publication
JNCI: Journal of the National Cancer Institute, 2015, Vol 107, Issue 6, p2
- ISSN
0027-8874
- Publication type
Article
- DOI
10.1093/jnci/djv162